Equities Analysts Issue Forecasts for Savara FY2030 Earnings

Savara Inc. (NASDAQ:SVRA) – Investment analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Savara in a report issued on Monday, March 9th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of $0.91 for the year. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share.

Several other analysts have also weighed in on SVRA. Oppenheimer set a $10.00 price objective on Savara in a report on Tuesday, December 23rd. Citizens Jmp reduced their target price on Savara from $11.00 to $10.00 and set a “market outperform” rating for the company in a research report on Thursday, November 13th. Guggenheim reiterated a “buy” rating on shares of Savara in a research note on Tuesday, December 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Thursday, January 22nd. Finally, Wells Fargo & Company increased their price objective on shares of Savara from $7.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.86.

Savara Trading Up 3.3%

Savara stock opened at $5.61 on Wednesday. The business has a 50 day moving average price of $5.70 and a two-hundred day moving average price of $4.92. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.32. Savara has a 12 month low of $1.89 and a 12 month high of $7.01. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -10.58 and a beta of 0.31.

Hedge Funds Weigh In On Savara

A number of hedge funds have recently modified their holdings of SVRA. Osaic Holdings Inc. boosted its stake in Savara by 6.9% in the 4th quarter. Osaic Holdings Inc. now owns 32,678 shares of the company’s stock valued at $197,000 after buying an additional 2,098 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Savara by 3.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 69,536 shares of the company’s stock worth $420,000 after acquiring an additional 2,116 shares in the last quarter. Graham Capital Management L.P. raised its stake in Savara by 4.9% during the fourth quarter. Graham Capital Management L.P. now owns 56,013 shares of the company’s stock worth $338,000 after acquiring an additional 2,615 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Savara by 9.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,155 shares of the company’s stock valued at $200,000 after acquiring an additional 2,859 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Savara by 48.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock valued at $60,000 after purchasing an additional 3,205 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.